Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Allergan plc AGN stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Allergan has a trailing twelve months PE ratio of 8.7, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 17.4. If we focus on the long-term PE trend, Allergan’s current PE level puts it much below its midpoint of 17.2 over the past five years, with the number having risen rapidly over the past few months.
Further, the stock’s PE also compares pretty favorably with the Medical Market’s trailing twelve months PE ratio, which stands at 20.4. At the very least, this indicates that the stock is much undervalued right now, compared to its peers.
We should also point out that Allergan has a forward PE ratio (price relative to this year’s earnings) of 8.9, which is tad higher than the current level. So it is fair to expect an increase in the company’s share price in the near term.
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, Allergan has a P/S ratio of about 3.1. This is slightly lower than the S&P 500 average, which comes in at 3.2x right now. Also, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.
If anything, AGN is lower than the mid-point of 5.5 of the time period from a P/S metric, suggesting some level of undervalued trading—at least compared to historical norms.
Broad Value Outlook
In aggregate, Allergan currently has a Value Score of B, putting it into the top 40% of all stocks we cover from this look. This makes Allergan a solid choice for value investors, and some of its other key metrics make this pretty clear too.
For example, the P/CF ratio for Allergan is 3.9, a level that is slightly lower than the industry average of 4.6x. Clearly, AGN is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though Allergan might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has Growth and Momentum Scores of B. This gives AGN a Zacks VGM score — or its overarching fundamental grade — of A. (You can read more about the Zacks Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been mixed at best. The current quarter has seen two upward revisions in the past sixty days compared to six downward revisions, while the full year estimate has seen ten upward and six downward revisions in the same time period.
This has had a mixed impact on the consensus estimate as the current quarter consensus estimate has declined by 5.1% in the past two months, while the full year estimate has inched up by 0.4%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
Allergan plc Price and Consensus
Allergan plc Price and Consensus | Allergan plc Quote
This somewhat mixed trend is why the stock has just a Zacks Rank #3 (Hold) and why we are looking for in-line performance from the company in the near term.
Allergan is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a sluggish industry rank (among Bottom 41% of more than 250 industries) and a Zacks Rank #3 it is hard to get too excited about this company overall.
In fact, over the past two years, the broader industry has clearly underperformed the market at large, as you can see below:
So, value investors might want to wait for estimates and industry rank to turn around in this name first, but once that happens, this stock could be a compelling pick.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Allergan plc (AGN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research